


OptraHEALTH



HealthFAX™



Conversational AI for Healthcare

Strengths

Pre-trained tasks

Clinical, health testing & operational scenarios



Built-in healthcare intelligence

Neurology, Cardiology, Chronic Diseases, Mental Health, Genetics etc.



Custom Data

Automated document processing & insights extraction, Intelligent Curation Workbench



Private instances

For use by clients and their users

Features

Conversationality

Contextual dialog flows | Health risk assessment | Clinical decision support | Report explanation

Cost Estimations

Benefits & Cost Estimations (live connectivity ~4000 payors)

Recommendations

Health Insights | Guidelines compliant | Automated Counseling

HealthGPT

Enterprise owned data with real world evidences | Custom Large Language models

ExpertConnect

Integrated tele-health | board certified health experts | Intelligent hand-off to experts

Operational Support

Appointments | Scheduling | Onboarding | Reminders | Consenting | Feedback | Proactive notifications to health coaches/ providers/ admins/ members | Integration with EMRs, LIMS | clinical labs | Custom software

MemberHUB

Dashboards & Business Insights | Analytics | Reports | Management

Technology

Compliances & Guidelines based rules engine

NLP

Machine Learning

Deep Learning

NLP

Deep Learning

NLP

Machine Learning

NLP

Machine Learning

HealthFAX™ Implementations

GeneFAX™ Digital Genetic Companion

Hi, I'm Quinn, your guide from Quest Diagnostics. I'm here to give you some background on **carrier screening**.

I'll explain why you might want to get screened and what your screening results may mean, so you can decide if carrier screening is right for you. **Before you get started, you should know.**

- Using this chatbot is optional, and your answers are kept 100% secure
- Your chat with me will take about 10 minutes, depending on which answers you select
- I'm provided by Quest Diagnostics and will educate you about genetic carrier screening. You will have the option to have a copy of the

Start

Powered by GeneFAX

Risk Assessment

Insurance

HealthGPT

AI Videos/ ExpertConnect

HealthFAX: Digital Navigator for Healthcare

contain any tingles or fever?

I have pulled out two pictures to help you.

It looks like clear liquid

Is there any discharge from the left ear?

No i dont think so

OK. Is there a swelling behind his right ear?

it see swelling but his ear appears pushed in front a

Continue

Powered by HealthFAX.ai

Risk Assessment

HealthGPT

AI Videos/ ExpertConnect

Bumrungrad International HOSPITAL

A complete family history may point to health risks not evaluated by this test.

It is important to note that while this test has found no genetic risk factors for certain types of conditions, at least a baseline, population-level risk remains for developing these types of disorders and age-appropriate screenings are still recommended.

You can also access educational resources about how your results can help inform your health.

Guide me through report

Sure, please select any one from the following.

Results

A detailed analysis of your DNA has revealed that you have tested Negative.

Tell me more **Test Panel** **Next Steps**

Powered by HealthFAX

Risk Assessment

HealthGPT

Return of Results

AI Videos/ ExpertConnect

Digital Cologuard Companion

Collection Preparation Shipping

Please avoid contaminating the container with urine, toilet paper, or any other material during sample collection process. Cross-contamination will interfere with the results of the test.

OK

Samuel, are you currently suffering from any of the following?

- Bleeding hemorrhoids
- Bleeding cuts or wounds on your hands
- Rectal bleeding
- Menstrual period
- Diarrhea

Yes **None of the above**

Why is this important?

Powered by HealthFAX.ai

Risk Assessment

HealthGPT

AI Videos/ ExpertConnect

HealthFAX™ Implementations

GeneFAX™ Digital Navigator for Genetic Health

Click [here](#) for a list of the 47 genes to be tested.

Continue

Each gene can be linked to an

BRCA Genes

Gene	Prostate Cancer	Ovarian Cancer	Colorectal Cancer	Uterine Cancer	Melanoma	Pancreatic Cancer	Esophageal Cancer	Prostate Cancer	Other Cancer
BRCA1	●	●				●		●	●
BRCA2	●	●			●			●	●

Close

OK, I understand the chart. Please continue

Would you like to have a copy of the 47 genes sent to your email?

Yes, I would like a copy. No

Powered by GeneFAX

Risk Assessment
HealthGPT

HealthFAX

Can you explain my report

AI Videos/ ExpertConnect

Activating Mutations in the Epidermal Growth Fa... 1 / 11 100% +

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812 MAY 20, 2004 VOL. 350 NO. 21

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib

Thomas J. Lynch, M.D., Daphne W. Bell, Ph.D., Raffaella Sordella, Ph.D., Saraa Gundhagatalla, M.D., Ross A. Okamoto, B.S., Brian W. Brannigan, B.A., Patricia L. Harris, M.S., Sara M. Hasserlat, B.A., Jeffrey G. Supek, Ph.D., Frank G. Halvick, M.D., Ph.D., David N. Louis, M.D., David C. Christiani, M.D., Jeff Settleman, Ph.D., and Daniel A. Haber, M.D., Ph.D.

ABSTRACT

BACKGROUND
Most patients with non-small-cell lung cancer have no response to the tyrosine kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR). However, about 10 percent of patients have a rapid and often dramatic clinical response. The molecular mechanisms underlying sensitivity to gefitinib are unknown.

METHODS
We searched for mutations in the EGFR gene in primary tumors from patients with non-small-cell lung cancer who had a response to gefitinib, those who did not have a response, and those who had not been exposed to gefitinib. The functional consequences of identified mutations were evaluated after the mutant proteins were expressed in cultured cells.

From the Cancer Center (T.J.L., D.W.B., R.S., R.A.O., B.W.B., P.L.H., S.M.H., J.G.S., F.G.H., D.N.L., D.C.C., J.S., D.A.H.) and the Department of Medicine (T.J.L., D.W.B., J.G.S., F.G.H., D.C.C., J.S., D.A.H.) and Pathology (D.N.L.), Memorial Sloan-Kettering Cancer Hospital and Harvard Medical School, and the Harvard School of Public Health (D.C., D.C.C.), all in Boston. Address reprint requests to Dr. Haber at MGH Cancer Center, 77 Ave. Louis Pasteur, Charlestown, MA 02129, or at haber@rics.bwh.harvard.edu.

Dr. Lynch, Bell, and Sordella contributed

HealthFAX Digital Navigator for Healthcare

Abstract Authors Methods Results Conclusions

Mutant proteins were expressed in cultured cells.

Describe the identified mutations?

Four tumors had in-frame deletions, removing amino acids 746 through 750 (delE746-A750) in Patient 1, 747 through 751 (delL747-T751ins5) in Patients 2, and 747 through 753 (delL747-T753ins3) in Patients 3 and 4.

Which patients responded best to Gefitinib?

Consistent with previous reports, we found that most patients with a response to gefitinib were women, had never smoked, and had bronchoalveolar tumors.

You might want to ask the following

Did any patients benefit from Gefitinib therapy?

What causes Gefitinib sensitivity?

What is Gefitinib?

Was Gefitinib added to samples?

Was Gefitinib added to samples?

Powered by HealthFAX

HealthGPT

... And many more